Download PDF
Klin Monbl Augenheilkd 2018; 235(04): 476-477
DOI: 10.1055/s-0043-124756
Der interessante Fall
Georg Thieme Verlag KG Stuttgart · New York

Efficacy of Natalizumab in Intermediate Uveitis Related to Multiple Sclerosis: A Case Report

Wirksamkeit von Natalizumab bei intermediärer Uveitis bei Multipler Sklerose: ein Fallbericht
Ségolène Roemer
1   Department of Ophthalmology, Jules Gonin Eye Hospital, University of Lausanne, Lausanne, Switzerland
,
Alexandre Bissig
1   Department of Ophthalmology, Jules Gonin Eye Hospital, University of Lausanne, Lausanne, Switzerland
,
Alda Rocca
2   Department of Clinical Neurosciences, Neurosurgery Unit, University Hospital CHUV, Lausanne, Switzerland
,
Renaud Du Pasquier
3   Laboratory of Neuroimmunology, Service of Neurology, Department of Clinical Neurosciences, University of Lausanne, CHUV, Lausanne, Switzerland
,
Yan Guex-Crosier
1   Department of Ophthalmology, Jules Gonin Eye Hospital, University of Lausanne, Lausanne, Switzerland
› Author Affiliations
Further Information

Publication History

received 26 September 2017

accepted 08 December 2017

Publication Date:
16 February 2018 (online)

Also available at
    Permissions and Reprints

Background

Tumefactive demyelinating lesions (TDL) usually correspond to solitary lesions greater than 2 cm, mimicking neoplasms in multiple sclerosis (MS). They are a rare presentation of MS and their prevalence is estimated to be 1 – 3/1000 cases with an incidence of 0.3/100 000 per year. Differentiating the diagnosis from primary brain neoplasms, like lymphoma or high-grade gliomas, remains challenging. Specific MRI features such as incomplete rim enhancement, high apparent diffusion coefficient values, and a large number of lesions can help the clinician. So far, corticosteroids and plasma exchange are the standard treatment. Introduction of immunosuppressive therapies clearly modified the course of relapsing-remitting MS but is still controversial in TDL [1]. The pathophysiological association between uveitis and MS has not yet been shown. Thus, specific treatment for this condition is not well defined.

Natalizumab (Tysabri®) is a humanized IgG4 monoclonal antibody directed against the α4 chain of integrins. It was previously used in the treatment of inflammatory bowel disease and was one of the first targeted therapies approved for relapsing forms of MS [2], [3]. But natalizumab therapy is also associated with an increased incidence of progressive leukoencephalitis. A stratification of the risk can be assessed by the anti-JC virus antibody index.

Prevalence of uveitis among MS patients varies greatly according to previous epidemiologic studies, but is approximatively 0.65 to 1.1% in large series [4]. Herein, we report an intermediate uveitis related to TDL, with a favorable evolution under natalizumab treatment, after a 1-year follow-up.

 

  • References

  • 1 Alghatani H, Shirah B, Alassiri A. Tumefactive demyelinating lesions: a comprehensive review. Mult Scler Relat Disord 2017; 14: 72-79
    CrossrefPubMedGoogle Scholar
  • 2 Ghosh S, Goldin E, Gordon FH. et al. Natalizumab for active Crohnʼs disease. N Engl J Med 2003; 348: 24-32
    CrossrefPubMedGoogle Scholar
  • 3 Brandstadter R, Katz Sand I. The use of natalizumab for multiple sclerosis. Neuropsychiatr Dis Treat 2017; 13: 1691-1702
    CrossrefPubMedGoogle Scholar
  • 4 Olsen TG, Frederiksen J. The association between multiple sclerosis and uveitis. Surv Ophthalmol 2017; 62: 89-95
    CrossrefPubMedGoogle Scholar
  • 5 Dwivedi RA, Dwivedi RE, Durnian JM. et al. Tumefactive demyelination: an unusual cause of a spontaneously resolving homonymous hemianopia. BMJ Case Rep 2013; DOI: 10.1136/bcr-2013-009363.
    PubMedGoogle Scholar
  • 6 Nakamura M, Itani K, Miyake K. et al. Natalizumab is effective for the treatment of relapsing-remitting tumefactive multiple sclerosis. Intern Med 2017; 56: 211-214
    CrossrefPubMedGoogle Scholar
  • 7 Jouve L, Benrabah R, Heron E. et al. Multiple sclerosis-related uveitis: does MS treatment affect uveitis course?. Ocul Immunol Inflam 2017; 25: 302-307
    PubMedGoogle Scholar